Furthermore, they showed that their nanovaccine synergized with a checkpoint blockade (anti-CTLA-4 + anti-PD-L1 cocktail) to block tumor growth in B16F10 melanoma and CT26 colon cancer mouse models. Here, CTLA4 is linked to neoplasm.